<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04214145</url>
  </required_header>
  <id_info>
    <org_study_id>OPCAB_vasopressor</org_study_id>
    <nct_id>NCT04214145</nct_id>
  </id_info>
  <brief_title>The Effect of Vasopressors on Cerebral Oxygentaion During Off Pump CABG</brief_title>
  <official_title>The Effect of Phenylephrine, Norepinephrine and Vasopressin on Cerebral Oxygentaion During Off Pump CABG: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to analyze the changes in cerebral oxygen saturation during the
      use of three vasopressors, phenylephrine, norepinephrine, and vasopressin, which are
      currently used during coronary artery bypass grafting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 7, 2020</start_date>
  <completion_date type="Anticipated">December 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 22, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cerebral oxygen saturation (%)</measure>
    <time_frame>during surgery</time_frame>
    <description>continuous monitoring of cerebral oxygen saturation during surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>during surgery</time_frame>
    <description>systolic/diastolic/mean blood pressure(mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate</measure>
    <time_frame>during surgery</time_frame>
    <description>heart rate(/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac index</measure>
    <time_frame>during surgery</time_frame>
    <description>cardiac index (L/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total amount of infused drug</measure>
    <time_frame>during surgery</time_frame>
    <description>Propofol, remifentanil, vasoacitve drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Input/output</measure>
    <time_frame>during surgery</time_frame>
    <description>Urine output, blood loss, amount of fluid and transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sublingual microscopy</measure>
    <time_frame>1) After induction, 2) lateral wall or posterior wall anastomosis (if possible) 3) skin closure</time_frame>
    <description>using SDF imaging device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular occlusion test</measure>
    <time_frame>1) After induction, 2) lateral wall or posterior wall anastomosis (if possible) 3) skin closure</time_frame>
    <description>using InspectraTM StO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Troponin I</measure>
    <time_frame>during surgery, at ICU admission, 24 hours / 48 hours after ICU admission</time_frame>
    <description>Troponin I (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lactate</measure>
    <time_frame>during surgery, at ICU admission, 24 hours / 48 hours after ICU admission</time_frame>
    <description>lactate (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>creatinine</measure>
    <time_frame>during surgery, at ICU admission, 24 hours / 48 hours after ICU admission</time_frame>
    <description>creatinine (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>albumin</measure>
    <time_frame>during surgery, at ICU admission, 24 hours / 48 hours after ICU admission</time_frame>
    <description>albumin (g/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NGAL</measure>
    <time_frame>during surgery, at ICU admission, 24 hours / 48 hours after ICU admission</time_frame>
    <description>NGAL (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACCE</measure>
    <time_frame>until 1 year after surgery</time_frame>
    <description>Major adverse cardiac and cerebrovascular events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AKI/RRT</measure>
    <time_frame>until 1 year after surgery</time_frame>
    <description>renal complication</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Cerebral Oxygen Saturation</condition>
  <arm_group>
    <arm_group_label>Phenylephrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Norepinephrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vasopressin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine</intervention_name>
    <description>Continuous infusion of Phenylenphrine 250 μg/mL (=Phenylephrine 10mg * 5@ + D5W 200 mL) if mean BP &lt; 60mmHg.
Initial rate: 0.42 μg/kg/min (=0.1 mL/kg/hr)
Increment by 0.21 μg/kg/min (=0.05 mL/kg/hr) if mean BP &lt; 60mmHg after 5 minutes
Maximum rate: 3.33 μg/kg/min (=0.8 mL/kg/hr)</description>
    <arm_group_label>Phenylephrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine</intervention_name>
    <description>Continuous infusion of Norepienphrine 20 μg/mL (=NE 4mg * 1@ + D5W 200 mL) if mean BP &lt; 60mmHg.
Initial rate: 0.03 μg/kg/min (=0.1 mL/kg/hr)
Increment by 0.015 μg/kg/min (=0.05 mL/kg/hr) if mean BP &lt; 60mmHg after 5 minutes
Maximum rate: 0.24 μg/kg/min (=0.8 mL/kg/hr)</description>
    <arm_group_label>Norepinephrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vasopressin</intervention_name>
    <description>Continuous infusion of Vasopressin 0.1 u/mL (=Vasopressin 20u * 1@ + D5W 200 mL) if mean BP &lt; 60mmHg.
Initial rate: 0.01 u/kg/hr (=0.1 mL/kg/hr)
Increment by 0.005 u/kg/hr (=0.05 mL/kg/hr) if mean BP &lt; 60mmHg after 5 minutes
Maximum rate: 0.08 u/kg/hr (=0.8 mL/kg/hr)</description>
    <arm_group_label>Vasopressin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing off pump coronary artery bypass.

        Exclusion Criteria:

          -  Patient refusal

          -  Preoperative vasopressor use

          -  Preoperative mechanical circulatory support

          -  Concurrent cerebrovascular or head and neck surgery

          -  Technical difficulty of measuring brain oxygen saturation

          -  Redo coronary artery bypass surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Anesthesiology and Pain Medicine, Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunseok Jeon</last_name>
      <phone>+82 2 2072 3108</phone>
      <email>jeonyunseok@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 22, 2019</study_first_submitted>
  <study_first_submitted_qc>December 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Yunseok Jeon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

